Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous versus intraventricular antimicrobial therapy for post-craniotomy bacterial meningitis
IRCT20260518069437N1Phase 3Recruiting
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Aug 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of meropenem, vancomycin and colistin in bacterial meningitis (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: 14-day mortality, Length of stay in ICU and 4 more. Started Aug 2026; status: recruiting.
02
Drugs
meropenemvancomycincolistin
03
Conditions
bacterial meningitis
Beyond the preview
Go deeper on IRCT20260518069437N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260518069437N1.